- Home
- ZIM vs GLPG Comparison
ZIM vs GLPG Comparison
Compare ZIM & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIM
- GLPG
- Stock Information
- Founded
- ZIM 1945
- GLPG 1999
- Country
- ZIM Israel
- GLPG Belgium
- Employees
- ZIM N/A
- GLPG N/A
- Industry
- ZIM Marine Transportation
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ZIM Consumer Discretionary
- GLPG Health Care
- Exchange
- ZIM Nasdaq
- GLPG Nasdaq
- Market Cap
- ZIM 2.0B
- GLPG 2.1B
- IPO Year
- ZIM 2021
- GLPG 2005
- Fundamental
- Price
- ZIM $13.32
- GLPG $31.91
- Analyst Decision
- ZIM Sell
- GLPG Sell
- Analyst Count
- ZIM 4
- GLPG 4
- Target Price
- ZIM $13.23
- GLPG $25.33
- AVG Volume (30 Days)
- ZIM 6.5M
- GLPG 246.1K
- Earning Date
- ZIM 08-20-2025
- GLPG 10-29-2025
- Dividend Yield
- ZIM 53.56%
- GLPG N/A
- EPS Growth
- ZIM N/A
- GLPG N/A
- EPS
- ZIM 16.63
- GLPG N/A
- Revenue
- ZIM $8,575,100,000.00
- GLPG $323,674,692.00
- Revenue This Year
- ZIM N/A
- GLPG N/A
- Revenue Next Year
- ZIM N/A
- GLPG N/A
- P/E Ratio
- ZIM $0.80
- GLPG N/A
- Revenue Growth
- ZIM 43.57
- GLPG 5.43
- 52 Week Low
- ZIM $11.04
- GLPG $22.36
- 52 Week High
- ZIM $30.15
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- ZIM 30.22
- GLPG 50.85
- Support Level
- ZIM $13.39
- GLPG $31.01
- Resistance Level
- ZIM $14.00
- GLPG $33.25
- Average True Range (ATR)
- ZIM 0.59
- GLPG 0.69
- MACD
- ZIM -0.20
- GLPG -0.15
- Stochastic Oscillator
- ZIM 0.00
- GLPG 43.58
About ZIM ZIM Integrated Shipping Services Ltd.
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.